Pharma News India Monthly (June 2026): Market Grows 13.3%, Sun Pharma's ₹271 Crore Deal & Q1 Earnings Preview

Namaste Readers!

Welcome to your monthly dose of Pharma News India Monthly.

June 2026 was a remarkable month for the Indian pharmaceutical industry. The domestic market grew at an impressive 13.3%, crossing ₹21,400 crore in monthly sales. Sun Pharma made a strategic ₹271 crore acquisition. Natco Pharma and Lupin received USFDA approval for a critical cancer drug. And industry experts began forecasting Q1 earnings with mixed expectations.

So grab your cup of chai ☕ and let me walk you through the latest pharmaceutical news in India in simple and easy language.

For more such monthly updates, keep visiting Greencrossindia.com/blog.

Quick Summary: Pharma News India This Month

Let me quickly list the top stories we are covering today:

  1. Indian pharmaceutical market grew 13.3% in June, crossing ₹21,478 crore in monthly sales
  2. Sun Pharma acquired Innovcare Lifesciences for ₹271 crore to strengthen product portfolio
  3. Natco Pharma and Lupin received USFDA approval for Eribulin Mesylate Injection
  4. Q1 FY27 earnings expected to decline up to 16% due to high base effect
  5. Mounjaro recorded 177.5% value growth but 32.7% unit sales decline
  6. 16 of top 40 pharma companies reported decline in unit sales in June
  7. Cardiac therapies remained largest segment with 16.1% growth
  8. Anti-diabetic therapies grew 18.8% to ₹2,085 crore
  9. Vaccines emerged as fastest-growing category with 17.2% growth
  10. Torrent, Zydus, Dr Reddy's reported value growth but unit sales declined
  11. Sun Pharma, Cipla, Lupin delivered double-digit growth in both value and units
  12. Novo Nordisk's once-weekly insulin Awiqli approved in India
  13. AstraZeneca secured ex-China license for COPD drug worth up to $1.9 billion
  14. Government prohibited 16 Fixed Dose Combinations
  15. CDSCO flagged 157 drug samples as Not of Standard Quality
  16. Eribulin Mesylate Injection approval for breast cancer treatment
  17. GSK to acquire Nuvalent for $10.6 billion in precision cancer therapies
  18. India needs quantum jump into high-value pharma manufacturing: Economists

Let me explain each story in simple terms.

1. Indian Pharma Market Grows 13.3% in June, Crosses ₹21,400 Crore

The biggest news this month in Pharma News India Monthly is the impressive growth of the domestic pharmaceutical market.

According to the latest data from Pharmarack Technologies, the Indian Pharmaceutical Market (IPM) recorded sales of ₹21,478 crore in June 2026, registering a 13.3% value growth over June 2025. Unit sales also grew 2.3%, indicating that growth was supported by both higher volumes and improved product mix.

What does this mean?

The June performance was significantly stronger than the market's 9.8% value growth recorded for the moving annual total (MAT). This reinforces the sustained momentum seen across the industry during the first half of 2026.

What did experts say?

Sheetal Sapale, Vice President – Commercial at Pharmarack Technologies, said: "The IPM has shown a value growth of 13.3 per cent with all the therapies showing positive value growth. Anti-Neoplastics and Vaccines are showing double-digit growth in both value and units."

Therapy-wise performance

Let me break down how different therapy segments performed:

  • Cardiac therapies remained the largest segment with 14% market share, sales of ₹3,090 crore, and 16.1% value growth
  • Anti-diabetic therapies grew 18.8% to ₹2,085 crore
  • Nutritionals expanded 16.3% to ₹2,047 crore
  • Anti-Infectives reported sales of ₹2,211 crore, growing 9.0%
  • Gastrointestinal therapies increased 8.3% to ₹2,641 crore
  • Respiratory therapies maintained double-digit momentum with 12.8% growth to ₹1,334 crore
  • Pain and Analgesics recorded sales of ₹1,486 crore, growing 11.2%
  • Neuro/CNS therapies expanded 14.8% to ₹1,457 crore
  • Dermatology remained resilient with 12.7% growth to ₹1,387 crore
  • Vaccines emerged as the fastest-growing category with 17.2% value growth and 16.5% unit growth
  • Anti-Neoplastics delivered 16.7% value growth and 10% unit growth
  • Urology outperformed with 19.3% value growth to ₹407 crore

My take on the market growth

This broad-based growth across all therapy segments is a positive sign. The fact that unit sales also grew 2.3% means this is not just price-led growth – people are actually consuming more medicines. The double-digit growth in chronic therapies like cardiac and anti-diabetic reflects the rising burden of lifestyle diseases in India.

2. Sun Pharma Acquires Innovcare Lifesciences for ₹271 Crore

In a strategic move, Sun Pharmaceutical Industries acquired Mumbai-based Innovcare Lifesciences for approximately ₹271.2 crore ($28.7 million) in an all-cash deal.

What is Innovcare Lifesciences?

Founded on July 21, 2014, Innovcare Lifesciences markets, distributes and sells pharmaceutical drugs, nutraceuticals and cosmeceutical products. The company operates only in India.

What are the financials?

Innovcare reported revenue from operations of ₹94.06 crore in FY26, up from ₹86.09 crore in FY25 and ₹80.93 crore in FY24. This shows steady growth over the years.

What did Sun Pharma say?

In an exchange filing on June 20, Sun Pharma said it has signed an agreement to acquire 100% of Innovcare's outstanding shares. The transaction is expected to close on or before July 31, 2026.

Sun Pharma described the acquisition as a "strategic investment to strengthen product portfolio of the Company."

Key details about the deal:

  • The acquisition does not constitute a related-party transaction
  • Neither promoters nor promoter group companies have any interest in Innovcare
  • No governmental or regulatory approvals are required for the deal
  • The deal will be paid for entirely in cash
  • Sun Pharma will get full ownership and control of Innovcare

The bigger picture – Organon deal

This acquisition comes after Sun Pharma signed a definitive agreement in April to acquire Organon for about **$11.75 billion**, including debt, at $14 per share. That transaction is expected to close by December, pending regulatory approvals.

Once completed, the Organon deal will be Sun Pharma's largest international acquisition and is expected to expand its presence in biosimilars, women's health and other specialty medicines.

What about financing?

According to a previous Bloomberg report, the State Bank of India is preparing to join a group of global lenders financing Sun Pharma's Organon acquisition. SBI is expected to commit as much as $1 billion, subject to board approval.

3. Natco Pharma and Lupin Receive USFDA Approval for Eribulin Mesylate Injection

Good news from the regulatory front.

Natco Pharma and Lupin Limited received approval from the U.S. Food and Drug Administration (USFDA) for Eribulin Mesylate Injection.

What is Eribulin Mesylate?

Eribulin Mesylate is a chemotherapy drug used in the treatment of breast cancer. It is the generic version of Eisai's Halaven.

What is the significance?

This approval allows both companies to market and sell the drug in the US market. The US is the largest pharmaceutical market globally, and generic approvals open up significant revenue opportunities.

Natco's strategic moves

Natco Pharma has been active in expanding its global footprint. The company is also set to acquire a significant stake in South Africa's Adcock Ingram, a 135-year-old firm, in a R4.2 billion deal. This acquisition will make Adcock Ingram a privately-held entity, co-owned by Natco and Bidvest.

According to reports, Natco's proposed all-cash deal to acquire nearly 36% of AIHL from minority shareholders is aimed at expanding its presence in South Africa, marking a strategic move to diversify beyond its core markets.

What is Adcock Ingram?

Adcock Ingram is South Africa's second-largest drugmaker. This acquisition provides Natco Pharma with a strong entry into high-growth African markets and expands its product offerings.

4. Q1 FY27 Earnings Preview: Mixed Expectations

The upcoming earnings season is generating significant interest.

According to Macquarie Capital, Nifty Pharma profits are expected to decline by up to 16% year-on-year for the April-June 2026 quarter.

Why the decline?

The high base from last year's generic cancer drug launches is weighing on comparisons. The sector, despite making up only about 3% of the Nifty 50, is expected to drag overall index earnings.

Company-wise expectations:

  • Dr Reddy's Laboratories: North America revenue could decline around 27% due to the absence of key generic products
  • Cipla: US business may fall about 15% due to a challenging base
  • Sun Pharma: Expected to post nearly 14% revenue growth, supported by its speciality portfolio
  • Aurobindo Pharma: May benefit from the launch of its generic cancer drug

What are analysts watching?

Investors will monitor updates on:

  • Sun Pharma's Organon acquisition progress
  • Dr Reddy's semaglutide launch timeline in Canada
  • Biocon's performance after the Mylan stake sale

What about currency impact?

Kunal Dhamesha, Pharma & Healthcare Research Analyst at Macquarie Capital, said currency depreciation should help export-focused drugmakers offset part of the earnings pressure.

"All these currency tailwinds are going to help offset some of the drag from the absence of key products," Dhamesha said, adding that higher raw material costs could weigh on profitability.

Domestic formulations outlook

Domestic formulations are expected to remain resilient, with growth of 13-15% driven by new launches and volume gains. The CDMO segment is also likely to perform well, with Divi's Laboratories and Neuland Laboratories expected to report strong growth.

Hospitals and diagnostics

Hospitals and diagnostics are forecast to be the strongest healthcare segment this quarter, led by healthy patient volumes and capacity additions at companies such as Apollo Hospitals, Fortis Healthcare, Jupiter Life, Dr Lal PathLabs and Metropolis Healthcare.

Semaglutide opportunity

Dhamesha expects Torrent Pharma, Sun Pharma and Lupin to lead India's semaglutide market, adding that "three to five years fast forward... the current top three or four companies... are going to come out as the winner."

5. Mounjaro: 177.5% Value Growth but 32.7% Unit Sales Decline

Eli Lilly's Mounjaro delivered an interesting performance in June.

The drug, which is the country's highest-selling brand during the month with sales of ₹102 crore, reported an impressive 177.5% value growth. However, unit sales declined 32.7%.

Why this divergence?

This reflects the rapid shift towards higher-strength and higher-value GLP-1 therapies. Patients are moving to more expensive dosage strengths, which drives value growth but doesn't necessarily increase prescription volumes.

The premiumisation trend

This is part of a broader trend. Five of India's top 20 pharmaceutical brands recorded a decline in unit sales during June 2026, even as several continued to post healthy growth in value. This highlights the growing divergence between revenue growth and prescription volumes.

Other brands with unit sales decline:

  • Cipla's Foracort: 9.2% value growth, 3.4% unit decline
  • Himalaya's Liv.52: 1.1% value decline, 9.5% unit fall
  • Alkem's Pan D: 1.3% value growth, 7.9% unit decline
  • Abbott's Udiliv: 5.7% value growth, 5.5% unit decline

Which brands performed well?

IPCA's Zerodol SP emerged as one of the strongest performers, registering 32.6% value growth and 23.7% unit growth. Torrent's Cilacar expanded 29.9% in value and 17.7% in units.

6. 16 of Top 40 Pharma Companies Report Decline in Unit Sales

This is an interesting trend that tells a story about the evolving market.

Sixteen of India's top 40 pharmaceutical companies recorded a decline in unit sales in June 2026, even as the IPM posted a robust 13.3% value growth.

What does this mean?

The trend highlights the widening gap between value and volume growth. Several companies are increasingly relying on premiumisation, product mix and price-led growth to drive revenues.

Which companies reported negative unit growth?

  • Torrent Pharmaceuticals: 15.7% value growth, 2.6% unit decline
  • Zydus: 18.4% value growth, 6.3% unit decline
  • Dr Reddy's Laboratories: 14.4% value growth, 2.4% unit decline
  • Emcure Pharmaceuticals: 3.6% value growth, 11.3% unit decline
  • GSK: 10.5% value growth, 1.1% unit decline
  • Eris Lifesciences: 9.0% value growth, 9.6% unit decline
  • Eli Lilly India: 100.7% value growth, 52.2% unit decline

Companies with healthy growth in both value and units:

  • Sun Pharma: 16.8% value growth, 7.3% unit growth
  • Cipla, Lupin, Intas, USV, Ajanta Pharma: Double-digit growth in both

What does this tell us?

Businesses with strong specialty, chronic care and innovative portfolios are sustaining momentum in both value and volumes. Several established players are relying more heavily on premium products to offset slower prescription growth.

7. Novo Nordisk's Once-Weekly Insulin Awiqli Approved in India

Good news for diabetes patients.

India has approved Awiqli (insulin icodec) for adults with both Type 1 and 2 diabetes. This is broader than the current US approval, which is only for use in Type 2 diabetes patients.

Why is this significant?

This is the first once-weekly basal insulin available in India. Instead of daily injections, patients can take it once a week. This significantly reduces the injection burden for diabetes patients.

What does it mean for patients?

  • Fewer injections per week (52 per year instead of 365)
  • Better convenience
  • Potentially improved adherence to treatment

8. AstraZeneca Secures Ex-China License for COPD Drug

AstraZeneca signed a significant licensing deal.

The company secured an ex-China license for Sino Biopharmaceutical's experimental COPD drug. The Chinese drugmaker is eligible to receive an upfront payment of $200 million**, with additional development, regulatory and sales milestones, totalling up to **$1.9 billion.

What is the drug?

The drug is an experimental treatment for Chronic Obstructive Pulmonary Disease (COPD), a common lung condition that makes it hard to breathe.

Why does this matter?

This shows the growing importance of respiratory therapies. COPD is a major health burden globally, and new treatments are in high demand.

9. Government Prohibits 16 Fixed Dose Combinations

In a regulatory move, the Ministry of Health and Family Welfare prohibited the manufacture, sale and distribution of 16 Fixed Dose Combinations (FDCs) for human use across India with immediate effect.

What are FDCs?

Fixed Dose Combinations are medicines that contain two or more active ingredients in a single dosage form.

Why were they banned?

The decision was taken under Section 26A of the Drugs and Cosmetics Act, 1940, following an extensive scientific review of drug combinations available in the Indian market. The move forms part of the government's ongoing efforts to ensure that only scientifically validated, safe and therapeutically justified medicines remain available to patients.

10. CDSCO Flags 157 Drug Samples as Not of Standard Quality

Quality control continues to be a focus area.

The Central Drugs Standard Control Organisation (CDSCO) released its monthly drug quality alert for May 2026, identifying 157 drug samples as Not of Standard Quality (NSQ) and 2 drug samples as Spurious following testing by Central and State Drug Testing Laboratories across the country.

Why does this matter?

This underscores the importance of continuous post-marketing surveillance to ensure the quality, safety and efficacy of medicines available to patients.

11. Other Important News (Quick Bites)

Let me quickly run through some other important stories from June 2026.

Kemwell Biopharma biosimilar progress

The Subject Expert Committee (SEC) on Dermatology & Allergy recommended granting permission to Kemwell Biopharma to conduct a comparative pharmacokinetic clinical study for its proposed Dupilumab biosimilar, ASP100.

Alembic Pharma USFDA tentative approval

Alembic Pharmaceuticals received tentative approval from the USFDA for Binimetinib Tablets, 45 mg. The drug is used in combination with encorafenib for the treatment of patients with specific forms of advanced cancer.

Aurobindo Pharma Lannett acquisition progress

Aurobindo Pharma moved closer to completing its strategic acquisition of U.S.-based generic drug manufacturer Lannett Company after the U.S. Federal Trade Commission (FTC) approved the transaction subject to certain divestiture conditions.

GSK to acquire Nuvalent for $10.6 billion

GSK announced an agreement to acquire Nuvalent, a clinical-stage biotechnology company focused on precision cancer therapies, in a transaction valued at approximately $10.6 billion.

Marksans Pharma acquires Germany-based ABCnow GmbH

Marksans Pharma entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH for approximately ₹10 crore.

Orchid Pharma licenses antibiotic Exblifep to Russia

Orchid Pharma licensed its antibiotic Exblifep to Russia's Pharmasyntez. Under the agreement, Pharmasyntez will hold exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form.

NITI Aayog report: Need quantum jump into high-value pharma

Commenting on the NITI Aayog report on pharmaceutical trade, economist Ved Jain said India needs to make a quantum jump into manufacturing high-value pharmaceuticals and APIs.

What This Means for You

Let me break it down by who you are.

If you are a patient:

  • More affordable biosimilars are entering the market – good news for treatment costs
  • Once-weekly insulin Awiqli is now approved in India – fewer injections for diabetes patients
  • The government is banning irrational drug combinations – safer medicines for everyone

If you are an investor:

  • Sun Pharma's ₹271 crore acquisition strengthens its domestic portfolio
  • Natco Pharma's USFDA approval and South Africa expansion are positive signs
  • Q1 earnings may be weak due to high base effect, but long-term outlook remains strong
  • Torrent, Sun Pharma and Lupin are expected to lead the semaglutide market

If you are a pharma professional:

  • The Indian pharma market is growing at 13.3% – strong demand across all therapy segments
  • Value growth is outpacing unit growth – premiumisation is a key trend
  • Quality control remains a regulatory priority with 157 NSQ samples flagged

FAQ – Pharma News Monthly India

Q: What are the top pharmaceutical trends for 2026?

A: Based on June 2026 data: Strong domestic market growth of 13.3% driven by chronic therapies. Premiumisation trend with value growth outpacing unit growth. Explosive growth in GLP-1 therapies (177.5% value growth for Mounjaro). Consolidation through M&A (Sun Pharma-Organon, Sun Pharma-Innovcare). Expansion of biosimilars in the US market. Once-weekly insulin approval. And increasing focus on specialty medicines.

Q: What are the latest pharma news updates this month (June 2026)?

A: Key updates include: Indian pharma market grew 13.3% to ₹21,478 crore. Sun Pharma acquired Innovcare Lifesciences for ₹271 crore. Natco Pharma and Lupin received USFDA approval for Eribulin Mesylate Injection. Q1 earnings expected to decline up to 16% due to high base. Mounjaro recorded 177.5% value growth but 32.7% unit decline. 16 of top 40 companies reported negative unit growth. Novo Nordisk's once-weekly insulin Awiqli approved in India. Government banned 16 Fixed Dose Combinations. CDSCO flagged 157 NSQ drug samples.

Q: Where can I find all monthly pharma industry news?

A: For comprehensive, curated monthly updates covering policy changes, market trends, and company-specific news in the Indian pharmaceutical sector, you can rely on Greencrossindia.com/blog.

Q: What is happening in the pharmaceutical industry this month?

A: The industry is navigating multiple developments. The domestic market is growing strongly at 13.3%. Companies are focusing on premiumisation and product mix to drive growth. M&A activity continues with Sun Pharma's strategic acquisition. Q1 earnings are expected to show weakness due to high base. The GLP-1 market is seeing explosive growth but with declining unit sales for some brands.

Q: Why are unit sales declining while value is growing?

A: This is driven by premiumisation – companies are shifting towards higher-strength and higher-value products. Patients are using more expensive dosage forms. Additionally, some companies are relying more on price-led growth rather than volume expansion to drive revenues.

Weekly Summary – Key Takeaways

Let me quickly wrap up this month's Pharma News India Monthly:

First, the Indian pharmaceutical market grew 13.3% in June to ₹21,478 crore, with all therapy segments showing positive value growth.

Second, Sun Pharma acquired Innovcare Lifesciences for ₹271 crore to strengthen its product portfolio. The company is also progressing on its $11.75 billion Organon acquisition.

Third, Natco Pharma and Lupin received USFDA approval for Eribulin Mesylate Injection for breast cancer treatment.

Fourth, Q1 FY27 earnings are expected to decline up to 16% due to the high base effect from last year's generic cancer drug launches.

Fifth, Mounjaro recorded 177.5% value growth but 32.7% unit sales decline, reflecting the shift towards higher-strength GLP-1 therapies.

Sixth, 16 of the top 40 pharma companies reported negative unit growth, highlighting the gap between value and volume growth.

Seventh, Novo Nordisk's once-weekly insulin Awiqli was approved in India for both Type 1 and 2 diabetes.

Eighth, the government banned 16 Fixed Dose Combinations and CDSCO flagged 157 NSQ drug samples.

Ninth, GSK announced a $10.6 billion acquisition of Nuvalent for precision cancer therapies.

Tenth, economists called for a quantum jump into high-value pharma manufacturing to boost exports.

Final Thoughts

June 2026 was a month of strong growth and strategic moves for the Indian pharmaceutical industry.

We are seeing:

  • Strong domestic demand – 13.3% market growth across all therapy segments
  • Premiumisation – value growth outpacing unit growth
  • M&A activity – Sun Pharma's strategic acquisition and the Organon deal progression
  • Regulatory focus – quality control and banning of irrational combinations
  • Innovation – once-weekly insulin approval and biosimilar progress

The high base effect from last year's generic drug launches may weigh on Q1 earnings, but the long-term outlook remains positive.

If you want to stay updated with the latest pharmaceutical news, keep following this monthly series.

For more updates, visit Greencrossindia.com/blog regularly.

That is all for this month, folks.

Found this useful? Share it with a colleague or friend who follows the pharma industry.

Got questions? Drop a comment below.

See you next month with more updates. Until then, take care!

Disclaimer: This article is for informational purposes only. The information is based on publicly available sources including news websites, magazines, and industry insights. Readers are advised to verify details independently before making any decisions related to health, business, or investment. Neither the author nor Greencrossindia.com is responsible for any errors, omissions, or outcomes arising from the use of this information.

Chat With Us On Whatsapp For Pcd Pharma Franchise